Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$13.94 USD
-0.28 (-1.97%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $13.94 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Dr. Reddy's Laboratories Ltd has a PEG ratio of 6.28 compared to the Medical - Generic Drugs industry's PEG ratio of 3.29.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RDY 13.94 -0.28(-1.97%)
Will RDY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RDY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RDY
Alvotech Gears Up to Report Q2 Earnings: Here's What to Expect
Dr. Reddy's Q1 Earnings Beat Estimates, Generics Sales Boost Revenues
RDY: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 18th
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
Other News for RDY
Dr Reddy's Laboratories Ltd (RDY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth ...
Wall Street Lunch: Return Of Meme Stock Frenzy Causes Volatility In The Market
Q1 2026 Dr Reddy's Laboratories Ltd Earnings Call Transcript
Dr. Reddy's (RDY) Plans Global Launch of Semaglutide Generic by 2026
Dr. Reddy’s to launch generic semaglutide in 87 countries: Bloomberg